Pharma Equity Group Takes a Bold Step Forward
Pharma Equity Group A/S, often referred to as PEG, has taken significant strides toward achieving its ambitious strategic objectives. Recently, the company entered into a Letter of Intent (LOI) to acquire the MedTech innovator Otiom A/S. This acquisition is set to reshape PEG’s focus, allowing it to broaden its portfolio and integrate advanced technologies into its offerings.
Understanding the Strategic Vision
PEG's shift towards becoming a leading player in the Life Science sector aligns with its goal of identifying and scaling Nordic innovation companies that are focused on solving pressing medical needs. The incorporation of Otiom A/S, known for its patented localization technology designed for dementia patients, signifies a strategic move to address a market with increasing demand and societal importance.
Otiom A/S: A Valuable Addition
Otiom A/S specializes in enhancing the safety and freedom of individuals suffering from dementia. Its IoT (Internet of Things) technology offers solutions that not only empower patients but also provide peace of mind to caregivers. This technology addresses a critical need in the healthcare sector, making Otiom an excellent fit for PEG's mission.
CEO's Vision: Execution and Value Creation
Christian Tange, the CEO of Pharma Equity Group, expressed enthusiasm regarding the acquisition, viewing it as concrete evidence of PEG’s commitment to diversifying its portfolio. He stated, "With Otiom, we deliver a proof-of-concept of our ability to execute on the company’s new strategy. This acquisition is about scaling a proven technology internationally, enhancing not only our offerings but also our market positioning."
Transaction Details and Expectations
The acquisition values Otiom A/S at an Enterprise Value of DKK 15 million. The structure of the transaction includes a share-for-share exchange, allowing Otiom’s current stakeholders to transition into co-shareholders in PEG. This mutual interest in long-term growth ensures a collaborative future.
Key Elements of the Transaction
- Clean Cut: Otiom will be acquired without internal debt, providing PEG with a streamlined platform for future operations.
- Management Incentives: The Otiom management team will remain engaged post-acquisition, in line with PEG's decentralized approach to management under a unified strategic vision.
About Otiom A/S: Innovations in Dementia Care
As a Danish MedTech firm, Otiom A/S stands out for its technological contributions to dementia care. Its systems are operational in 24 countries with over 9,700 units produced. The company, which has established a robust market presence and partnerships across the EU, continues to see expansion in regions like DACHNL and maintains a strong position in Denmark.
Performance and Financial Highlights
Otiom A/S operates close to breakeven, generating approximately DKK 1.5 million in quarterly revenue, amounting to an annualized revenue of DKK 8 million. The company also handles a high number of active situations, showing the robustness of its technology and systems.
Looking Forward: The Next Steps
In light of the acquisition, PEG is initiating a Due Diligence process that concentrates on key areas including intellectual property, commercial plans, and legal considerations. A final Share Purchase Agreement is anticipated to be reached shortly, paving the way for seamless integration.
The market is encouraged to stay informed as PEG enhances communication strategies, reflecting transparency and commitment to stakeholders.
For additional inquiries, please reach out to:
Christian Tange, CEO, Pharma Equity Group A/S, phone: +45 2948 8417, email: ct@pharmaequitygroup.com
Christian Vinding Thomsen, Chairman of the Board, Pharma Equity Group A/S, phone: +45 2622 7222, email: cvt@loevenlaw.dk
Frequently Asked Questions
What is the main goal of Pharma Equity Group's acquisition?
The primary goal is to enhance its portfolio by incorporating a company that aligns with its strategy of addressing unmet medical needs and accelerating time-to-market for innovative technologies.
How does Otiom A/S contribute to Pharma Equity Group?
Otiom A/S brings patented technology for dementia care, allowing PEG to expand beyond pharmaceuticals into commercially viable MedTech solutions.
What financial structure is involved in the acquisition?
The acquisition is structured as a share-for-share exchange, ensuring that the current owners of Otiom become co-shareholders in PEG.
How is PEG planning to manage the integration of Otiom?
PEG intends to retain Otiom's management, allowing for a smooth transition and sustained operational engagement in line with PEG’s strategic governance.
When is the expected completion date for the acquisition?
The final Share Purchase Agreement is expected to be signed by the end of January 2026, contingent on the results of due diligence.
